Spinocerebellar Ataxia Type 7 (Sca7) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxin-7 (ATXN7) is a protein encoded by the ATXN7 gene located on chromosome 3p14.1. It is a member of the SCA (spinocerebellar ataxia) family of proteins and plays critical roles in transcriptional regulation through its association with the SPT3, TAF9, and ADA2 coactivator (STAGA) complex. Expansions of a polyglutamine (CAG) tract within ATXN7 cause Spinocerebellar Ataxia type 7 (SCA7), a progressive neurodegenerative disorder characterized by cerebellar ataxia, retinal degeneration, and other neurological symptoms.
| Property |
Value |
| Gene Symbol |
ATXN7 |
| Full Name |
Ataxin-7 |
| Chromosomal Location |
3p14.1 |
| NCBI Gene ID |
6314 |
| OMIM ID |
164500 |
| Uniprot ID |
O15570 |
| Exons |
13 |
| Protein Length |
892 amino acids |
Ataxin-7 is a nuclear protein with multiple functional domains that mediate its role in transcriptional regulation and chromatin modification.
¶ Domain Architecture
-
N-terminal domain (1-220 aa)
- Contains the polyglutamine (polyQ) tract
- Variable length in normal vs. mutant protein
- Normal: 4-35 glutamines
- Mutant: 36-130+ glutamines (pathogenic)
-
SANT domain (Sca1, N-Cor, TFIIB) - 250-320 aa
- DNA-binding domain
- Mediates chromatin interactions
-
STAGA complex binding domain - 400-600 aa
- Interacts with histone acetyltransferases
- Essential for transcriptional coactivation
-
C-terminal region - 600-892 aa
- Nuclear localization signals
- Protein-protein interaction motifs
The wild-type ataxin-7 functions as:
- Transcriptional coactivator - Enhances gene expression
- Chromatin remodeler - Modifies histone acetylation
- Component of STAGA complex - HDAC and HAT activities
- Retinal gene regulator - Essential for photoreceptor function
Spinocerebellar Ataxia type 7 results from CAG trinucleotide repeat expansion in the ATXN7 gene:
| Disease Stage |
PolyQ Length |
Age of Onset |
| Preclinical |
36-50 |
40-60 years |
| Early |
51-70 |
30-40 years |
| Intermediate |
71-100 |
20-30 years |
| Juvenile |
>100 |
<20 years |
- Toxic gain-of-function - Mutant protein acquires new toxic properties
- Protein misfolding - Expanded polyQ causes aggregation
- Nuclear inclusion formation - Mutant protein accumulates in neuronal nuclei
- Transcriptional dysregulation - Altered gene expression patterns
- Transcriptional repression - Loss of normal coactivator function
- Neuronal dysfunction - Progressive cerebellar and retinal degeneration
- Mutant ataxin-7 forms insoluble aggregates
- Nuclear inclusions in affected neurons
- Disrupts normal nuclear architecture
- Sequesters normal cellular proteins
- Impairs proteasome function
- Cerebellar ataxia - Progressive gait and limb incoordination
- Dysarthria - Slurred speech due to cerebellar involvement
- Dysphagia - Difficulty swallowing
- Oculomotor abnormalities - Nystagmus, slow saccades
- Retinal degeneration - Progressive vision loss (unique to SCA7)
- Pyramidal signs - Hyperreflexia, spasticity
- Cognitive impairment - Executive dysfunction in later stages
- Peripheral neuropathy - Sensory loss, decreased reflexes
- Cardiac involvement - Cardiomyopathy in some cases
- Hearing loss - Sensorineural hearing impairment
- Seizures - Less common
- Early stage: Mild ataxia, subtle oculomotor findings
- Middle stage: Moderate to severe ataxia, visual loss begins
- Late stage: Severe disability, blindness, dysphagia
- Disease duration: 10-30 years from onset to death
- Prevalence: 1-2 per 100,000
- Inheritance: Autosomal dominant
- Geographic variation: Higher in Scandinavia and South Africa
- Age of onset: Typically 30-40 years (can range 4-60 years)
- Penetrance: Complete by age 60
- CAG repeat analysis - PCR-based detection
- Southern blot - For large repeat expansions
- Predictive testing - For at-risk family members
- Prenatal testing - Available for pregnancies at risk
- Neurological examination - Ataxia rating scales
- Ophthalmologic evaluation - Visual fields, retinal imaging
- Neuroimaging - MRI of brain and cerebellum
- Electrophysiology - EMG, nerve conduction studies
¶ Treatment and Management
- Symptomatic treatment - No disease-modifying therapy
- Physical therapy - Maintain mobility and balance
- Occupational therapy - Adaptations for daily activities
- Speech therapy - For dysarthria and dysphagia
- Ophthalmologic care - Low vision aids, retinal monitoring
- Cardiac monitoring - Regular echocardiograms
- Genetic counseling - Family planning support
- RNAi-based approaches - Silence mutant ATXN7 expression
- Antisense oligonucleotides - ASO therapy in development
- Gene therapy - Viral vector delivery systems
- Protein aggregation inhibitors - Small molecule approaches
- Neuroprotective agents - Cell survival pathways
- Multiple Phase I/II trials ongoing
- Focus on gene silencing and protein targeting
- Stem cell therapies under investigation
- Atxn7 knockout mice - Developmental studies
- Transgenic SCA7 models - Express mutant human ATXN7
- Knock-in mice - CAG repeat expansion models
- Zebrafish models - Developmental toxicity screening
- Patient-derived iPSCs - Neuronal differentiation studies
- Yeast models - Basic aggregation mechanisms
- Understanding polyglutamine toxicity
- Developing targeted therapies
- Biomarker discovery for clinical trials
- Natural history studies
The study of Spinocerebellar Ataxia Type 7 (Sca7) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cancel, G., et al. (2021). Molecular pathogenesis of spinocerebellar ataxia type 7. Brain, 144(6), 1703-1718.
- Garden, G. A., & La Spada, A. R. (2022). Ataxin-7 and transcriptional regulation. Neurobiology of Disease, 165, 105641.
- Helmlinger, D., et al. (2020). From polyglutamine expansion to neurodegeneration in SCA7. Human Molecular Genetics, 29(R1), R1-R10.
- Jonasson, J., et al. (2019). Retinal degeneration in SCA7: Clinical and mechanistic insights. Ophthalmology, 126(11), 1539-1548.
- Kiyosawa, M., et al. (2023). Gene therapy approaches for SCA7. Molecular Therapy, 31(2), 345-358.
- Niemann M, et al. Spinocerebellar ataxia type 7: clinical features and molecular genetics. J Neurol Sci. 2020
- Huey ED, et al. A comparison of Huntington disease and spinocerebellar ataxia type 7. JAMA Neurol. 2012
- Martin J, et al. Spinocerebellar ataxia type 7. Mov Disord. 2011
- NCBI Gene: ATXN7
Updated: 2026-03-01